Press Releases
Bio-Hermes Clinical Trial Launches to Compare Biomarker Tests; Seeks Rapid, Less Expensive Diagnostics for Alzheimer’s Disease
Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – [email protected], 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]
Inland Northwest Research Screens First Patient Worldwide for Study of Investigational Parkinson’s Disease Drug
GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]
Statement to the FDA on Support for Aducanumab for Treatment of Early Stage AD
GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]
Lilly’s TRAILBLAZER-ALZ 2 Trial is Partnering with the Global Alzheimer’s Platform Foundation® to Shatter the Slow Completion Timeframes of Alzheimer’s Clinical Trials
TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]
STATEMENT: ELI LILLY’S PHASE 2 DONANEMAB STUDY RESULT IS CAUSE FOR CELEBRATION
Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s […]
STATEMENT: BIOGEN AND APPLE PARTNERSHIP SPEEDS SEARCH FOR ALZHEIMER’S TEST; SHOULD PRIORITIZE DIVERSITY
Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI): Today’s announcement by Biogen and Apple marks a significant step on the path to early […]
Investment in Diversity and Rapid, Early Diagnostics Is Essential to the Search for a Cure for Alzheimer’s Disease
Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, […]
STATEMENT: NEW DATA PLATFORM WILL EXPEDITE INNOVATION AND DRIVE COLLABORATION FOR ALZHEIMER’S DISEASE RESEARCH
Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench. “Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly […]
Global Alzheimer’s Platform Foundation® President Testifies before FDA Advisory Committee in Support of Breakthrough Alzheimer’s Drug
GAP President John Dwyer says aducanumab offers disease-modifying benefit significantly exceeding current therapies Contact: Pamela Larkin, 408-466-5952, [email protected] Washington, DC (November 6, 2020) – Today, the President of the Global Alzheimer’s Platform Foundation® (GAP), John Dwyer, testified before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee regarding Biogen’s breakthrough Alzheimer’s drug aducanumab. Given that clinical […]
STATEMENT: BLOOD TEST FOR ALZHEIMER’S IS A MAJOR ADVANCEMENT FOR PATIENTS, RESEARCHERS & PHYSICIANS
Contact: Pamela Larkin, 408-466-5952, [email protected] Washington, DC (October 29, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding C2N Diagnostics’ release of the PrecivityADTM blood test. “Congratulations to the C2N Diagnostics team for successfully developing the first blood test of its kind for Alzheimer’s disease. It will transform […]